Figure 2: Flow chart of the CILT study. Derived from an optimal two-stage design for a phase II clinical trial with the following parameters: $p_0 = 0.8$, $p_1 = 0.95$, error probability $\alpha = 0.05$, and error probability $\beta = 0.2$. Abbr.: $n$, number of patients; $r$, maximum number of responders at which $H_0$ will not be rejected; $H_1$, alternative hypothesis.